

### SOST Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP17391a

#### **Specification**

#### SOST Antibody (N-term) Blocking Peptide - Product Information

**Primary Accession** 

**Q9BQB4** 

# SOST Antibody (N-term) Blocking Peptide - Additional Information

**Gene ID 50964** 

Other Names Sclerostin, SOST

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

# **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

#### SOST Antibody (N-term) Blocking Peptide - Protein Information

Name SOST (HGNC:13771)

#### **Function**

Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.

# **Cellular Location**

Secreted, extracellular space, extracellular matrix


# **Tissue Location**

Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteoblasts differentiated for 21 days. Detected in the subendothelial layer of the aortic intima (at protein level).

#### SOST Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides





# SOST Antibody (N-term) Blocking Peptide - Images SOST Antibody (N-term) Blocking Peptide - Background

Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN(differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with anautosomal-recessive disorder, sclerosteosis, which causesprogressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with amilder form of the disorder called van Buchem disease. [provided byRefSeq].

### SOST Antibody (N-term) Blocking Peptide - References

van Lierop, A.H., et al. Eur. J. Endocrinol. 163(5):833-837(2010)Liu, J.M., et al. J. Clin. Endocrinol. Metab. 95 (9), E112-E120 (2010): Paternoster, L., et al. J. Clin. Endocrinol. Metab. 95(8):3940-3948(2010)Piters, E., et al. Hum. Mutat. 31 (7), E1526-E1543 (2010):Collette, N.M., et al. Dev. Biol. 342(2):169-179(2010)